The Valley Desk

Clinical trial reportBloodPublished

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Blood
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Bispecific; Antibodies, Monoclonal; Adult; Aged; Aged, 80 and over; Middle Aged; Female
PubMed ID
40983036
Added to directory
Source checked

Report a correction or request removal